Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietCardiovascularOncologyIssue 729

Resveratrol May Not Be Associated with Improved Health

The antioxidant resveratrol, found in red wine, chocolate and grapes, was not associated with longevity or the incidence of cardiovascular disease, cancer and inflammation in a new study.... 

Advertisement

The "French Paradox" of a low incidence of coronary heart disease despite a diet high in cholesterol and saturated fat in France has been attributed to the regular intake of red wine and, in particular, to resveratrol and other polyphenols contained in wine. Some preliminary evidence also suggests that resveratrol may have anti-inflammatory effects, prevent cancer, and decrease blood vessel stiffness.

For the study, the participants (a sample of 783 men and women 65 years or older) were part of the Aging in the Chianti Region study from 1998 to 2009 in two Italian villages. The authors investigated whether resveratrol levels achieved through diet were associated with inflammation, cancer, cardiovascular disease, and death. Levels were measured using 24 hour urine collections to look for breakdown products of resveratrol.

The results showed that, during nine years of follow-up, 268 participants (34.3 percent) died; of the 639 participants free of cardiovascular disease at enrollment, 174 (27.2 percent) developed cardiovascular disease during the follow-up; and of the 734 participants who were free of cancer at enrollment, 34 (4.6 percent) developed cancer during the follow-up. Urine resveratrol metabolite levels were not associated with death, inflammation, cardiovascular disease or cancer.

Researchers concluded that this prospective study of nearly 800 older community-dwelling adults shows no association between urinary resveratrol metabolites and longevity. This study suggests that dietary resveratrol from Western diets in community-dwelling older adults does not have a substantial influence on inflammation, cardiovascular disease, cancer, or longevity.

Practice Pearls:
  • The "French Paradox" may not exist
  • Resveratrol found in red wine, chocolate and grapes was not associated with longevity or the incidence of cardiovascular disease, cancer and inflammation

JAMA Intern Med. Published online May 12, 2014. doi:10.1001/jamainternmed.2014.1582.  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  DietCardiovascularOncologyIssue 729

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75